Review anchor
Kappa-type opioid receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Kappa-type opioid receptor
CHEMBL237
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Kappa-type opioid receptor as ChEMBL target CHEMBL237, mapped to UniProt P41145. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL237
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P41145
Kappa-type opioid receptor
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Kappa-type opioid receptor matters
Kappa-type opioid receptor is reviewed as Kappa-type opioid receptor (UniProt P41145); Kappa-type opioid receptor shows approved-linked disease relevance led by pain. 5 more disease programs remain visible in the same review block.; 4 linked drugs keep this evidence frame grounded.; the current evidence base includes 103 approved drugs, 10303 compounds, and 1761 assays, with lead potency reaching pChEMBL 11.0.
Protein context
Kappa-type opioid receptor
Kappa-type opioid receptor Sequence length is 380 aa.
Review this target as Kappa-type opioid receptor, mapped to UniProt P41145. Sequence length is 380 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P41145
Protein
Disease context
pain
Kappa-type opioid receptor shows approved-linked disease relevance led by pain. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AXOMADOL, BUPRENORPHINE, DEZOCINE.
Start review with pain because it currently carries approved-linked support. Linked drugs include AXOMADOL, BUPRENORPHINE, DEZOCINE, DIFELIKEFALIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
4 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 103 approved drugs, 10303 compounds, and 1761 assays for this target. The dominant activity type is KI. CHEMBL415247 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL415247 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
103 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Kappa-type opioid receptor matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P41145, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why pain is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
10303
Total Compounds
1761
Total Assays
103
Approved Drugs
IC50: 4308.0, KI: 6231.0, EC50: 2617.0, KD: 19.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL415247
|
11.0 | Ki | — |
|
|
No preferred name
CHEMBL2338747
|
11.0 | EC50 | — |
|
|
No preferred name
CHEMBL4111684
|
10.9 | EC50 | — |
|
|
No preferred name
CHEMBL2338720
|
10.9 | EC50 | — |
|
|
No preferred name
CHEMBL4109154
|
10.8 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
SAMIDORPHAN
CHEMBL426084
|
2021 |
|
|
DIFELIKEFALIN
CHEMBL3989915
|
2021 |
|
|
LASMIDITAN
CHEMBL3039520
|
2020 |
|
|
NALFURAFINE HYDROCHLORIDE
CHEMBL490665
|
2009 |
|
|
NALFURAFINE
CHEMBL267495
|
2009 |
|
|
METHYLNALTREXONE
CHEMBL1186579
|
2008 |
|
|
ALVIMOPAN
CHEMBL270190
|
2008 |
|
|
CINACALCET HYDROCHLORIDE
CHEMBL1200776
|
2004 |
|
|
BISACODYL
CHEMBL942
|
2004 |
|
|
RALOXIFENE
CHEMBL81
|
1997 |
|
|
NALMEFENE
CHEMBL982
|
1995 |
|
|
TRAMADOL
CHEMBL1237044
|
1995 |
|
|
LEVORPHANOL
CHEMBL592
|
1991 |
|
|
NALTREXONE
CHEMBL19019
|
1984 |
|
|
NALTREXONE HYDROCHLORIDE
CHEMBL1201149
|
1984 |
|
|
MORPHINE
CHEMBL70
|
1984 |
|
|
PIMOZIDE
CHEMBL1423
|
1984 |
|
|
HYDROMORPHONE
CHEMBL398707
|
1984 |
|
|
HALOPROGIN
CHEMBL1289
|
1982 |
|
|
GENTIAN VIOLET
CHEMBL64894
|
1982 |
|
|
BUPRENORPHINE
CHEMBL511142
|
1981 |
|
|
BUPRENORPHINE HYDROCHLORIDE
CHEMBL2368861
|
1981 |
|
|
NALBUPHINE
CHEMBL895
|
1979 |
|
|
BUTORPHANOL
CHEMBL33986
|
1978 |
|
|
LOPERAMIDE HYDROCHLORIDE
CHEMBL1707
|
1976 |
|
|
NALOXONE
CHEMBL80
|
1971 |
|
|
NALOXONE HYDROCHLORIDE
CHEMBL1718
|
1971 |
|
|
FENTANYL
CHEMBL596
|
1968 |
|
|
PENTAZOCINE
CHEMBL100116
|
1967 |
|
|
THIORIDAZINE
CHEMBL479
|
1962 |
|
|
OXYMORPHONE
CHEMBL963
|
1959 |
|
|
METHADONE
CHEMBL651
|
1947 |
|
|
HYDROCODONE
CHEMBL1457
|
1943 |
Source Header